The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
16-Jan-98
$NA
Target:
Borden Foods International
Acquiror:
Nestlé S.A.
Advised Nestlé on its acquisition of Borden Foods International’s businesses, which have sales of more than $400 million.
17-Jul-00
$10.5 billion
Target:
Diageo plc
Acquiror:
General Mills, Inc.
Advised Diageo on the sale of The Pillsbury Company for $5.1 billion in assumed debt and $5.4 billion in stock to General Mills.
19-Dec-00
$8.2 billion
Target:
Seagram
Acquiror:
Diageo plc and Pernod Ricard
(Spirits Division)
Advised Diageo on its joint agreed bid with Pernod Ricard for Seagram’s spirits business.
16-Jan-01
$11.5 billion
Target:
Ralston Purina Co.
Acquiror:
Nestlé S.A.
Advised Nestlé on the agreed cash offer for the US pet-food company Ralston Purina
30-Oct-02
$588 million
Target:
T&S Stores Plc
Acquiror:
Tesco PLC
Advised Tesco PLC, Britain’s largest retailing group, on its acquisition of T&S Stores plc, a publicly listed convenience store retailer operating in the UK.
13-Dec-02
$1.5 billion
Target:
Burger King Corp
Acquiror:
Texas Pacific Group, Bain Capital, Goldman Sachs Capital Partners
(subsidiary of Diageo plc) Advised Diageo plc on sale of Burger King Corporation restaurant system.
18-Mar-03
$7.0 billion
Target:
Wella AG
Acquiror:
The Procter & Gamble Company
Advised Wella AG, a global market leader in hair care and fragrances, on its sale to The Procter & Gamble Company
23-Oct-03
$3.1 billion
Target:
Debenhams plc
Acquiror:
Baroness Retail (a consortium of CVC, TPG and Merrill Lynch)
Advised the independent committee of the Board of Directors of Debenhams plc, a leading UK department store chain, with regards to the sale of the company
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
12-Apr-06
$NA
Target:
WH Smith PLC
Advised WH Smith PLC on the demerger of its Retail business
15-Dec-06
$19.1 billion
Target:
Gallaher Group plc
Acquiror:
Japan Tobacco Inc.
Advised Gallaher Group plc, the world’s fifth largest tobacco company, on a recommended cash offer from Japan Tobacco Inc
18-Dec-06
$NA
Target:
InBev SA
Acquiror:
Mr. Wolfgang Dinkelacker
Advised InBev SA, the world's largest brewery, on the sale of German regional brewery Dinkelacker-Schwaben Bräu KG
30-Mar-07
$24.4 billion
Target:
Alliance Boots plc
Acquiror:
Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
Advised Alliance Boots plc, the leading international pharmacy-led health and beauty group, on a proposal regarding an offer for the company from a consortium comprising of Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
08-Jun-07
$448 million
Target:
Dobbies Garden Centres plc
Acquiror:
Tesco plc
Acted as financial adviser to Tesco plc on its recommended acquisition of Dobbies Garden Centres plc, one of the UK's largest garden centre retailers
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
21-May-08
$85 million
Target:
Dobbies Garden Centres plc
Acquiror:
Tesco plc
Advised Tesco plc in relation to its public cash offer to acquire the 35% of Dobbies Garden Centres plc which it does not already own
28-Jul-08
$2.1 billion
Target:
Tesco Personal Finance Group Limited
Acquiror:
Tesco plc
Advised Tesco plc in relation to its acquisition of the 50% interest it does not already own in Tesco Personal Finance Group Limited, a joint venture with The Royal Bank of Scotland Group plc. Tesco Personal Finance offers a range of retail insurance and banking products under the Tesco brand
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
10-Mar-10
$576 million
Target:
Camelot Group plc
Acquiror:
Ontario Teachers’ Pensions Plan
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
11-Feb-11
$986 million
Target:
Findel plc
Advised Findel plc, a UK listed multi-channel retailer, on the restructuring of its balance sheet comprising an equity capital raising and refinancing of its debt and pension obligations